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Abstract
Changes in the distribution of the proton magnetic resonance spectroscopy (MRS) observed metabolites N-acetyl aspartate
(NAA), total-choline (Cho), and total-creatine (Cre) in the entire intracranial corticospinal tract (CST) including the primary
motor cortex were evaluated in patients with amyotrophic lateral sclerosis (ALS). The study included 38 sporadic definite-
ALS subjects and 70 age-matched control subjects. All received whole-brain MR imaging and spectroscopic imaging scans
at 3T and clinical neurological assessments including percentage maximum forced vital capacity (FVC) and upper motor
neuron (UMN) function. Differences in each individual metabolite and its ratio distributions were evaluated in the entire
intracranial CST and in five segments along the length of the CST (at the levels of precentral gyrus (PCG), centrum semiovale
(CS), corona radiata (CR), posterior limb of internal capsule (PLIC) and cerebral peduncle (CP)). Major findings included
significantly decreased NAA and increased Cho and Cho/NAA in the entire intracranial CST, with the largest differences for
Cho/NAA in all the groups. Significant correlations between Cho/NAA in the entire intracranial CST and the right finger tap
rate were noted. Of the ten bilateral CST segments, significantly decreased NAA in 4 segments, increased Cho in 5 segments
and increased Cho/NAA in all the segments were found. Significant left versus right CST asymmetries were found only in
ALS for Cho/NAA in the CS. Among the significant correlations found between Cho/NAA and the clinical assessments
included the left-PCG versus FVC and right finger tap rate, left -CR versus FVC and right finger tap rate, and left PLIC versus
FVC and right foot tap rate. These results demonstrate that a significant and bilaterally asymmetric alteration of metabolites
occurs along the length of the entire intracranial CST in ALS, and the MRS metrics in the segments correlate with measures
of disease severity and UMN function.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease characterized by progressive degeneration of both upper
motor neurons (UMN) in the primary motor cortex (PMC) and
lower motor neurons (LMN) in the brain stem and spinal cord
anterior horns. Despite identification of pathologies in the PMC
and corticospinal tracts (CST) of autopsy tissue samples with ALS
[1,2], there are no biomarkers identified to date that reliably
indicate presence of such pathologies in the brain of patients with
ALS. In an effort to find neuroimaging biomarkers indicative of
UMN degeneration, advanced MR techniques (e.g., magnetic
resonance spectroscopy, diffusion tensor imaging and functional
MRI) have been explored [3,4]. It is hypothesized that the
neuropathologically proven motor neuron and CST degeneration
in ALS might occur gradually with no apparent manifestation of
macroscopic tissue structural changes in the early stage that are
detectable by conventional MRI methods. In contrast, neuro-
chemicals indicative of metabolic processes responsible for
degeneration of the motor neurons and CST in patients with
ALS can be accessed from the disease onset stage using proton
MR spectroscopic (MRS) methods. Proton MRS enables non-
invasive measurement of brain metabolites [5] such as N-acetyl
aspartate (NAA; a marker of viability of neurons), total-choline
(Cho; an indicator of cell membrane structural integrity, synthesis
and degradation; MRS signal sum of all choline-moiety containing
compounds), and total-creatine (Cre; an indicator of cellular
energetics; MRS signal sum of creatine and phosphocreatine).
Several previous cross-sectional and longitudinal studies have
demonstrated the value of proton MRS for evaluation of
metabolite alterations in the PMC [6,7,8,9,10,11,12,13,14,15,16]
and CST [11,17] of patients with ALS using single voxel (SVS)
and 2D MR spectroscopic imaging [11,17,18,19] (MRSI)
methods. In general, most of these studies have reported
significantly altered metabolite concentrations or ratios in the
motor pathways of patients with ALS.
The data acquisition in these studies has been based on manual
selection of relevant anatomical regions such as PMC and
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within manually selected ROIs in the case of MRSI. Manual
selection of anatomical regions in longitudinal studies is susceptible
to user-subjectivity, increasing the probability of error in obtaining
data from the same anatomical volume in follow up studies. This is
then likely to contribute to increased variance in group
comparisons and follow-up studies.
The objective of this methodological study was to develop user-
independent and comprehensive MRSI data acquisition and
analysis methods for evaluating metabolite changes in the
intracranial CST in patients with ALS. Towards achieving this,
our unique volumetric proton MRSI acquisition method was used
to acquire data from the whole-brain of patients with ALS and
controls. A new atlas-based data analysis approach was introduced
to evaluate metabolite values in the entire 3D-anatomical volume
of the intracranial CST (the length of the tract from the PMC to
the cerebral peduncle). Furthermore, the length of the CST was
segmented into five discrete but contiguous anatomical regions to
evaluate metabolite variations in each of the segments and to
assess if any anatomical segment has degraded preferentially over
the others in ALS. Finally, metrics from the metabolite and clinical
measures were correlated to assess associations between the
measures. Our specific hypothesis is that metabolite analysis in
patients with ALS using the entire volume of the intracranial CST
and its segments will provide new insight on the extent of
metabolite changes along the intracranial CST bilaterally and the
association between metabolite measures in the CST (intracranial
CST as a whole and its segments) and clinical measures.
Methods
Subject Selection
Thirty eight subjects (52.368.8 years; 26 males; 4 left handed)
that met the revised El Escorial criteria [20] for sporadic definite-
ALS were recruited from the Kessenich Family MDA ALS
Center, University of Miami for inclusion in this study. Though all
consecutive subjects with ALS were screened for participation in
this study, only those who met the standard 3T MRI pre-screening
procedure for scanning and were healthy enough to lie on their
back with minimal body motion for the duration of the MRI scan
were selected for this study. Sixteen subjects were treated with
riluzole either before participating in this study or at the time of
scan, and the duration of their riluzole treatment varied between 2
weeks and 32 months prior to the scan. For comparison, data from
a group of 70 control subjects (51.966.3 years; 27 males) were
included and all were recruited from the local community. For
selecting control subjects, standard MRI prescreening procedures
were used to exclude subjects with MRI contraindications,
previous brain injury or surgery, or a history of neurological
disease, psychiatric illness or substance abuse. The study protocol
was approved by the institutional review board of University of
Miami, and all subjects provided signed written consent before
participation.
Neurological Assessments
Subjects with ALS received detailed physical and neurological
examinations by a neurologist (KRS). The clinical assessment
included evaluating hand and leg muscle stretch reflexes, muscle
tone, disease severity and upper motor neuron function. Disease
severity was evaluated using the ALS Functional Rating Scale-
Revised (ALSFRS-R; [21]) and percentage of predicted forced
vital capacity (% FVC). The ALSFRS-R score ranges from 0 to 48
with 0 and 48 indicating total disability and no disability,
respectively. The functional status of the pyramidal tracts, an
indicator of upper motor neuron disability, was quantified by
counting the number of rapid foot taps, finger taps, lip movements
with ‘pa-pa’ syllable repeats and tongue movements with ‘la-la’
syllable repeats, each in 10 s [22,23], and the counts were
converted to rates (per second scores). The above measurements
were performed twice during the same session with an interval of
1 minute in between for obtaining the representative average rate
for each of the muscle sites assessed.
For the remainder of this paper, measures of UMN function
constitute the rates of rapid foot and finger taps, lip movements
with ‘pa-pa’ syllable repeats and tongue movements with ‘la-la’
syllable repeats, measures of disease severity include the ALSFRS-
R score and % maximum of predicted FVC, clinical measures
indicate measures of UMN function and disease severity, and
MRS metrics include concentrations of NAA, Cre and Cho
(provided in institutional units) and Cho/NAA ratio.
Magnetic resonance imaging and spectroscopy
MR data were acquired at 3 Tesla (Siemens TimTrio) using an
eight-channel phased-array head coil for detection. An hour-long
MR protocol was used, consisting of structural MRI (T1-
weighted), diagnostically relevant MRI and whole-brain MRSI
acquisitions. The MRI sequences included T1-weighted
(MPRAGE; TE/TR: 2.38 ms/2300 ms, TI: 900 ms, 160 slices,
1m m
3 isotropic resolution, and ,5.2 min.), FLAIR (TE/TR:
101 ms/9 s, 33 slices, 4 mm slice thickness, field of view (FOV):
2206220 mm
2, and ,2.2 min.) and T2-weighted turbo spin-echo
MRIs (TE/TR: 87 ms/6.4 s, 33 slices, 4 mm slice thickness, FOV
2206220 mm
2, and ,2.2 min.).
MRSI data were acquired using a volumetric spin-echo EPSI
sequence (TR/TE: 1710 ms/70 ms, FOV: 28062806180 mm
3,
100650618 spatial points, 135 mm excitation slab, and acquisi-
tion time of 26 min.). The sequence acquires two datasets, a spin-
echo metabolite dataset and a low flip-angle (20u) gradient-echo
water reference dataset. It includes frequency-selective water
suppression, and inversion recovery nulling of the extra-cranial
lipid signal with a TI of 198 ms. Additional details of the data
acquisition were provided in our earlier publications [23,24].
Data processing and analysis
MRSI data were processed using the MIDAS package [25].
Briefly, data imported into the MIDAS environment went through
a pipeline of processing steps that included formation of
volumetric metabolite images, co-registration of T1-MRI and
MRSI, segmentation of T1-MRI, calculation of MRSI voxel tissue
content based on segmentation of the T1-weighted MRI, signal
normalization to institutional units using the tissue water reference
signal and tissue content information from the same voxel, and
spatial registration to the Montreal Neurological Institute (MNI)
single-subject MRI template [26] at 2 mm
3 isotropic resolution.
For spectral fitting, metabolite prior information for NAA, Cre
and Cho were simulated using an in-house developed program
that used the GAMMA library [27] and published chemical shifts
and coupling constants [5]. The nominal MRSI voxel volume as
acquired was approximately 0.3 mL (5.665.6610=314 mm
3).
After zero-padding the data to a 64664632 matrix and applying
Gaussian spatial smoothing in the three orthogonal directions, the
voxel volume used for data analysis was approximately 1 mL.
Metabolite data analysis was performed in the MNI template
space using a single-subject probabilistic CST atlas [28,29]. From
this atlas, only voxels with the probability values .0.20 were
included to create a modified atlas for data analysis. Furthermore,
it was divided into five segments at anatomically appropriate levels
in the superior-inferior direction, namely, precentral gyrus (PCG),
Corticospinal Tract Metabolites in ALS
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internal capsule (PLIC) and cerebral peduncle (CP). Metabolite
values (NAA, Cre, Cho) and Cho/NAA ratio in voxels within the
right and left side of the entire intracranial CST atlas and its five
segments were obtained. For each of the regions in the atlas,
metabolite values were first corrected for partial volume signal loss
due to CSF contribution at each voxel and then, mean metabolite
values and ratios were calculated.
For statistical analyses, three data selection criteria were applied
to ensure the quality of the data chosen. First, a line-width
criterion was applied to only include voxels with fitted spectral
line-width between 2 and 12 Hz. Next, a fractional tissue volume
criterion was applied to only include voxels with underlying tissue
volume of $70%. Finally, an outlier exclusion criterion was
applied to exclude voxels with metabolite values greater than three
times the standard deviation of the corresponding metabolite value
over all the voxels within the particular region. This last criterion
was applied separately for each metabolite value and ratio.
Statistical tests
The metabolite measures (NAA, Cho, Cre, and Cho/NAA) of
the ALS and control subject groups in both the entire intracranial
CST and its segments in each hemisphere were compared using
analysis of covariance (ANCOVA) test. To control for possible
confounding effects of age and gender, we included effects for age,
gender, and the interactions of these two variables with group.
After testing the full model, we found no significant interactions of
group and gender for any of the analyses. Therefore, this
interaction was deleted from subsequent models. Significant
interactions were found for group and age in several analyses;
therefore we included separate effects for age dependent on group,
i.e. we nested age in group to provide a separate slopes model.
We used a linear mixed model to perform a repeated measures
ANOVA to evaluate left intracranial-CST versus right intracra-
nial-CST metabolite asymmetries separately for the entire
intracranial CST and its segments. The same test was used to
evaluate differences in metabolite values between the segments
along the intracranial CST in each hemisphere. The model
included group (ALS vs. Control), age nested in group (separate
slopes model), and gender as fixed effects and person nested in
group as the random effect.
For evaluating associations between Cho/NAA and the
measures of UMN function and disease severity, Pearson’s product
moment partial correlation was used, and the results are reported
as correlation coefficients (r-values) between the scores or values of
the two measures. Handedness information was not included in
this test as the patient population was overwhelmingly right-
handed (34 right-handed and 4 left-handed), making any results
based on handedness unstable.
P-values of ,0.05 were considered to be significant for all the
tests performed. To account for multiple testing, an appropriate
Bonferroni correction was applied to the p-values of the tests
performed to adjust for the four metabolite data measures (NAA,
Cre, Cho and Cho/NAA) in each of the regions, two hemispheric
CST (left, right) and five anatomical segments (PCG, CS, CR,
PLIC and CP) within each hemispheric CST (i.e., px4 for the
between group CST metabolite comparisons in each hemisphere,
or px4x2 for the left-CST versus right-CST metabolite compar-
isons in each group, and px4x5 for the comparisons between the
segments in each hemispheric CST in each group), thereby
maintaining the same significance level (p,0.05).
Results
Disease duration, severity and metrics of clinical
measures
Disease duration and severity (ALSFRS-R and FVC) of the
patients in the ALS group are provided in Table 1. Disease
durations were calculated from the symptom onset date to the date
of the MRI scan. The clinical measures of motor neuron function
for the patients in the ALS group are provided in Table 2.
Spectral quality and CST atlas
Representative 1H MR spectra obtained from six anatomical
regions along the length of the CST between the precentral gyrus
and cerebral peduncle of a patient with ALS (male, 43 year old)
are shown in Figure 1. Each spectrum was obtained by averaging
over a number of contiguous voxels in the same region. As seen in
the figure, the quality of spectra is good across all regions,
including from the medulla and pons/midbrain.
In Figure 2 are shown the entire intracranial CST atlas [28,29]
and its modified version used for data analysis. The probability
cutoff used (.0.20) is seen to limit the neuronal WM fiber
arborization, thereby including only the fiber bundles that are
definitively part of the CST for analysis.
Metabolite differences between the ALS and control
groups in the CST
In Figure 3 are shown comparisons of the metabolite values and
Cho/NAA ratio for the ALS and control groups for the entire
intracranial CST. As shown, significant group differences
(indicated by asterisks) were observed for NAA, Cho and Cho/
NAA in both the left and right entire intracranial CST whereas
there were no significant differences for Cre. The significant
percent metabolite differences found in the ALS group as
compared to the control subject group were: 28.9% (left) and
26.2% (right) for NAA, 8.1% (left) and 7.5% (right) for Cho, and
20.0% (left)and 15.7% (right) for Cho/NAA, respectively.
In Figure 4 are shown the five contiguous segments (PCG, CS,
CR, PLIC and CP) along the length of the CST between the PMC
and cerebral peduncle, and a simplified motor homunculus
indicating the somatotopic arrangement for the face and upper
and lower limbs. In Figure 5 are shown comparisons of the
metabolite metrics obtained in the five segments of the bilateral
intracranial CST of the ALS and control groups. In general, there
was a consistent bilateral trend of either increased (Cho or Cho/
NAA) or decreased (NAA) metabolite values in the ALS group as
compared to the control group. Significant group differences were
noted for NAA in 4 of the 5 segments in the left CST (except in the
CP), for Cho in 2 segments in the left CST (in the CS and CR) and
3 segments in the right CST (in the PCG, CS and CR), and for
Cho/NAA in all the segments of CST bilaterally. The significant
percentage differences observed for Cho/NAA ranged from
+9.5% in the CP of the right CST to +24.5% in the CS of the
left CST.
Inter and intra-hemispheric differences for metabolites in
the intracranial CST
Comparisons between the left and right
hemisphere. There were no significant metabolite differences
in the entire intracranial CST (data not shown) in both the ALS
and control subject groups. However, in the segments of the
intracranial CST (data not shown), there was a significant left
versus right difference for Cho/NAA in the CS segment in the
Corticospinal Tract Metabolites in ALS
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Measure Description Value Type ALS Group (n=38)
Disease duration (months) since noticing symptoms mean6SD 29627
median 18
range 2–120
since diagnosis mean6SD 18623
median 7
range 1–83
ALSFRS-R* score mean6SD 3767
median 37
range 22–48
Forced vital capacity % predicted mean6SD 79618
median 80
range 41–125
*Amyotrophic lateral sclerosis functional rating scale-revised.
doi:10.1371/journal.pone.0035607.t001
Table 2. Clinical measures of motor neuron function in the ALS group.
Measure Description Value Type ALS Group (n=38)
Handedness right handed number of subjects 34
left handed number of subjects 4
Finger tapping rate* right hand mean6SD 2.560.9
median 2.5
range 0.9–4.2
left hand mean6SD 2.560.9
median 2.5
range 0.7–4.1
mean of right and left mean6SD 2.560.7
median 2.5
range 0.9–4.1
Foot tapping rate* right leg mean6SD 2.161.1
median 2.2
range 0.0–4.7
left leg mean6SD 2.061.1
median 2.0
range 0.0–5.1
mean of right and left mean6SD 2.161.1
median 2.1
range 0.0–4.9
La-la syllable repeat rate* tongue muscle mean6SD 3.461.1
median 3.4
range 0.8–5.0
Pa-pa syllable repeat rate* lip muscle mean6SD 3.460.9
median 3.4
range 0.9–5.1
Bulbar muscle syllable repeat rate* tongue and lip muscles** mean6SD 3.461.0
median 3.5
range 0.8–5.0
*Rates are provided in s
21;
**mean of la-la and pa-pa syllable repeat rates.
doi:10.1371/journal.pone.0035607.t002
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any of the segments in the control group.
Comparisons between the segments within each
hemisphere. In Tables 3 and 4 are shown the p-values of the
between segments metabolite comparisons in each hemispheric
CST for the control and ALS subject groups, respectively
(mean6SD are shown in Figure 5). Significant metabolite
differences were noted for 34 out of 40 possible comparisons in
the left (p=0.031 to ,0.0001) and 30 in the right hemispheric
segments (p=0.015 to ,0.0001) for the controls, and 24 in the left
(p=0.043 to ,0.0001) and 17 (p=0.030 to ,0.0001) in the right
hemispheric segments for the ALS group.
Associations between the metabolite and clinical
measures
In the entire intracranial CST of the ALS group, significant
negative correlations were observed between Cho/NAA in the left
CST versus FVC (r=20.332, p=0.042), and Cho/NAA in the
bilateral CST versus right finger tap rate (left side: r=20.589 6,
p=,0.0001; right side: r=20.490 5, p=0.002). The correlation
between Cho/NAA in the right CST and left finger tap rate also
approached towards significance (r=20.304, p=0.064).
In the segments of the CST of the ALS group, the significant
correlations noted between Cho/NAA and the measures of UMN
function and disease severity were: the left PCG versus FVC
(r=20.412, p=0.010) and right finger tap rate (r=20.502,
p=0.001), the left CS versus FVC (r=20.367, p=0.023) and
right finger tap rate (r=20.485, p=0.002), and the left PLIC
versus FVC (r=20.327, p=0.045) and right foot tap rate
(r=20.326, p=0.046).
Figure 1. Representative
1H-MR spectra in the brain of a patient with ALS.
1H-MR spectra obtained at 3T from six anatomical regions
(square boxes on the MRIs) along the length of the corticospinal tract in the brain of a patient with ALS (male, 43 years) are shown. (a: medulla; b:
pons/midbrain, c: left internal capsule; d: left corona radiata; e: left centrum semiovale; f: left precentral gyrus/subcortical white matter). The spectra
shown were obtained by averaging spectra from 2.7 mL to 6.0 mL contiguous voxels in that region.
doi:10.1371/journal.pone.0035607.g001
Figure 2. Intracranial corticospinal tract atlas. The full-range
probabilistic atlas is shown in green. We modified this atlas (shown in
red) for our use by including only voxels with probability values greater
than 0.20 and by excluding voxels inferior to the cerebral peduncle. The
axial MRI image is included to provide anatomical context.
doi:10.1371/journal.pone.0035607.g002
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in the entire intracranial CST and its segments and other clinical
measures such as foot tap rates, syllable repeat rates, etc.
Discussion
In this study a comprehensive evaluation of
1H-MRS observed
cerebral metabolite alterations in the primary motor cortex and
corticospinal tract of patients with ALS was performed. For the
purpose of finer analysis of metabolite alterations, the intracranial
CST was divided into 5 anatomically distinct segments. Data
analysis was performed at the volume levels of the entire
intracranial CST and its segments bilaterally. Furthermore,
correlations between the MRS measures and the clinical measures
of UMN function and disease severity were evaluated to find
associations between the measures.
The main findings of this study were: (1) Data from the whole
anatomical volume of the primary motor cortex and CST in
controls and patients with ALS can be obtained conveniently using
a whole-brain MRSI acquisition method; the availability of whole-
brain MRSI data enabled us to use an intracranial CST atlas that
eliminated user-subjectivity in selecting volumes (or ROIs) for
metabolite evaluation. (2) Significant changes in NAA, Cho, Cho/
NAA of the entire intracranial CST in the ALS group, and on a
finer level, significant NAA decreases in 4 of the 5 segments in the
left CST, significant Cho increases in 2 and 3 segments in the left
and right intracranial CST, respectively, and significant Cho/
NAA increases in all the CST segments bilaterally. (3) A significant
left versus right intracranial CST difference for Cho/NAA in the
CS segment in the ALS group. (4) Fewer number of comparisons
of metabolites between the segments in each hemispheric CST
showed significant differences in ALS as compared to controls. (5)
Significant correlations between Cho/NAA in the entire intracra-
nial CST of patients with ALS and their disease severity or UMN
function measures (FVC and finger tap rate), and on a finer level,
significant correlations between Cho/NAA of 3 intracranial CST
segments (left-PCG, left-CS and left-PLIC) and disease severity
and UMN function measures.
Previous single voxel [6,9,13,30] and MRSI [11,16,18,19]
studies in patients with ALS have manually selected the
anatomical locations for data acquisition and/or analysis along
the length of CST between the primary motor cortex and the
cerebral peduncle. Such a data acquisition or analysis approach
has inherent user-subjectivity and inevitably includes data from
non-motor pathways, both of which are likely to contribute to
increased variance in group comparison studies. In contrast, the
volumetric MRSI acquisition method used in this study acquired
data from the whole-brain encompassing the entire bilateral
Figure 3. Comparison of intracranial corticospinal tract (CST) metabolite values between the ALS and control groups. Comparisons of
the left (A) and right (B) entire intracranial corticospinal tract (CST) metabolite values (mean 6 SD) in the ALS (n=38) and control (n=70) groups (age
range: 34–65 years) using ANCOVA. The green and orange histograms indicate the metabolite values of the entire intracranial CST in the ALS and
control groups, respectively. The asterisks indicate significant group differences with *p,0.05, **p,0.005 and ***p,0.0001. The significant percent
differences found were: 28.9 (left) and 26.2 (right) in NAA, +8.1 (left) and +7.5 (right) in Cho, and +20.0 (left) and +15.7 (right) in Cho/NAA. The
abbreviations used indicate as NAA: N-acetyl aspartate; Cre: total-creatine; Cho: total-choline; I. U.: institutional units.
doi:10.1371/journal.pone.0035607.g003
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used for data analysis, which eliminated user-subjectivity in
selection of the volumes for evaluation. This comprehensive and
template based approach is well suited for evaluating the spatial
and temporal changes in metabolites in longitudinal and treatment
efficacy studies in ALS and other brain pathologies.
The results from this study cannot directly be compared with
previous studies in literature as no studies have used the approach
of whole-brain data acquisition and template based analysis, apart
from the fact that the acquisition sequence parameters used in this
study (specifically, the echo time) are different from those used in
previous studies. However, in general terms, our results agree with
most previous MRS studies that have evaluated the cerebral
metabolite concentration or ratio changes, at least in a part of the
intracranial CST in patients with ALS. In the case of NAA and
NAA/Cho, a few previous studies [9,10,12,14,15,16,18,19,
31,32,33] have reported results similar to ours. In our data
analysis, significant changes in NAA or Cho/NAA were found in
the entire intracranial CST of patients with ALS (Figure 3). The
percentage differences of metabolite values in ALS as compared to
controls ranged from 26.2% to 28.9% for NAA and +15.7% to
+20.0% for Cho/NAA. In an intra-subject MRSI reproducibility
study [34] that used the same acquisition sequence as this study,
the coefficients of variation (COVs) reported were 1.3% and 1.9%
for NAA in the frontal and parietal lobes, respectively, and 2.9%
and 2.7% for Cho/NAA in the same two lobar regions,
respectively. At the spatial resolution of the whole-brain MRSI
data used for analysis in this study (,1 mL), the intracranial CST
can be considered to be co-localized in both frontal and parietal
lobes of the brain. Thus, it can be inferred from the above COV
information that the percentage metabolite differences observed
between the ALS and control groups in this study would remain
significant even after accounting for the test-retest variability of the
MRS metrics used in this study.
NAA is present almost exclusively in neurons [5,35], and so the
decrease in its concentration in a brain region is indicative of
reduced neuronal density due to its loss or reduced neuronal cell
volume due to progressive neurodegeneration or metabolically
dysfunctional albeit structurally intact neurons. The neuropatho-
logical features found in the primary motor cortex and CST of
most ALS autopsy cases include loss of motor neurons,
intracytoplasmic inclusions and cytoplasmic shrinkage in surviving
motor neurons, atrophy of the motor cortex, and degeneration of
the CST [1,2]. The reduced NAA found in patients with ALS in
this study is consistent with the above mentioned autopsy findings
in ALS.
Significantly increased Cho was found bilaterally in the entire
intracranial CST of patients with ALS (Figure 3). The increased
Cho ranged from +7.5% to +8.1%. Similar to this study, previous
MRS studies in the motor cortex (or the precentral gyrus) of
patients with ALS have also reported significantly increased Cho
[6] or Cho/Cre [10,14,19,33,36].
The proton MR observed Cho signal in the brain has major
contributions from the membrane constituents, glycerophospho-
choline and phosphocholine, and a minor contribution from free
choline [5]. In ALS, neuropathological studies [1,2] have found
loss of large myelinated white matter fibers together with variable
astrocytic gliosis and lipid laden macrophages in the degenerated
primary motor tracts. Our results suggest that patients in the early
stage of the disease are likely to have ongoing inflammation in
their motor pathways; presence of such an inflammatory process
could be an indicator of degradation of the motor neuron
membranes that results in increased Cho MRS signal, as broken
down membranes are known to be more ‘‘visible’’ in MRS than
structurally intact membranes. As the disease progresses, over a
period of time, the motor neuron degeneration in the primary
motor cortex and CST causes glial cells to fill up the space left
behind by the degenerated membranes leading to an increase in
Cho MRS signal. Once both degeneration of membranes in the
primary motor cortex and CST and its concomitant glial cell
proliferation are completed, no more change in Cho is expected
(i.e., flooring of metabolite changes).
No significant group differences were found for Cre in the entire
intracranial CST of the ALS group as compared to the control
group (Figure 3). Similar findings were reported by previous
studies [6,12,31,32] although two studies have reported signifi-
cantly decreased Cre in ALS [10,14]. The proton MRS observed
Cre signal in the brain at 3T has contributions from creatine and
phosphocreatine [7]. The creatine-phosphocreatine and its
concomitant ATP-ADP shuttles in the brain cellular energetics
ensure a stable concentration of Cre detectable by proton MRS,
though it is known to be altered in some brain pathologies [5]. Our
observation of no significant difference in Cre indicates that there
was no net change in Cre concentration within the cellular
components of the entire intracranial CST in ALS. Metabolite
ratios to Cre (NAA/Cre and Cho/Cre) were, thus, not included in
this analysis.
There were no significant metabolite differences between the
entire left and right intracranial CST in both the control and ALS
groups. However, the observation of a significant Cho/NAA
difference between the left and right centrum semiovale segments
Figure 4. Segmented intracranial corticospinal tract (CST) atlas
and the somatotopic arrangement within the primary motor
cortex. The probabilistic corticospinal tract (CST) atlas is overlaid onto
the coronal orientation T1-MRI template (Montreal Neurological
Institute). The color bar indicates the full range of the probability
values in the CST atlas. The horizontal lines indicate the approximate
anatomical levels at which the five segments were made along the
length of the CST. PCG: Precentral gyrus, CS: Centrum semiovale, CR:
Corona radiata, PLIC: Posterior limb of the internal capsule, CP: Cerebral
peduncle and R: Right side of the subject. The blue, green and purple
lines indicate the somatotopic arrangement within the primary motor
cortex that are associated with the face and lower and upper limb parts,
respectively.
doi:10.1371/journal.pone.0035607.g004
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alterations along the CST. Furthermore, the above results suggest
that the intracranial CST data analysis by segments is a more
sensitive evaluation method than by the entire intracranial CST
method for detecting regional changes along the CST in ALS.
Finding such localized metabolite changes in the early stage of
disease will allow us to characterize the disease onset location
within the brain and its spread over a period of time in individuals.
Also, the observed metabolite bilateral asymmetry in ALS
advocates for correlating the metabolite data from the left and
right CST separately with clinical measures rather than combining
the data from both the sides.
The findings of significant metabolite differences between
majority of the intracranial CST segments in each hemisphere
in both the control (Table 3; 64 out of 80 comparisons) and ALS
groups (Table 4; 41 comparisons) indicate that the metabolite
concentrations along the CST segments are significantly hetero-
geneous. However, the number of significant differences observed
in the ALS group was less than that observed in the control group
(41 in ALS versus 64 in controls). This could be because the extent
of tissue degeneration was different in different segments of the
CST in the patient population. These disease-induced varying
levels of metabolite alterations along the length of the CST in ALS
can be better quantified using the finer segmented CST analysis.
However, it should be emphasized that the possible variation in
the severity and/or progression of disease in the patient population
might also have contributed to the difference in significance levels
seen here and further longitudinal studies might be needed to
investigate this.
Our results showed significant correlations only between Cho/
NAA in the entire intracranial CST of the ALS group and FVC
and finger tap rates. At a finer level, significant negative
Figure 5. Metabolite metrics in the length of the intracranial corticospinal tracts in the ALS and control groups. Metabolite metrics
along the length of the intracranial corticospinal tracts (CST) in patients with ALS (blue; n=38) and control (red; n=70) groups in the age range of
34–65 years using ANCOVA. The asterisks indicate significant group differences with *p,0.05, **p,0.005 and ***p,0.0001. The abbreviations used
indicate as NAA: N-acetyl aspartate, Cho: total-choline, Cre: total-creatine, PCG: precentral gyrus, CS: centrum semiovale, CR: corona radiata, PLIC:
posterior limb of internal capsule, CP: cerebral peduncle, and I.U.: institutional units.
doi:10.1371/journal.pone.0035607.g005
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segments in the left CST and clinical measures of FVC and right
finger and foot tap rates were observed. The observed negative
correlation between Cho/NAA in the left CST and right finger
tap rate (r=20.59, p,0.0001) is an expected association as there
is a contralateral anatomical relationship between the regions
localizing the upper limb somatotopies in the primary motor
cortex and their associated body parts of the upper limbs.
However, the similarly expected correlation between Cho/NAA in
the right CST and left finger tap rate has a trend towards
significance (p=0.064), possibly due to a slightly less number of
patients with left upper limb weakness included in this study (10
patients with left upper limb weakness versus 13 patients with right
upper limb weakness). The observed correlations of Cho/NAA in
the entire intracranial CST with only finger tap rates (see Results
section) and not with the foot tap rates and the syllable repeat
(assessing the bulbar muscles) rates can be explained by comparing
the CST atlas and the motor homunculus [37] shown in Figure 4.
The atlas at the cortical and subcortical levels within the primary
cortex only encompasses the voxels localizing the upper limb
somatotopies and not the foot and face somatotopic regions. Also
inferred from the figure is that the length of the CST atlas between
the corona radiata and the cerebral peduncle includes WM fibers
fanning out towards the motor cortex regions representing the foot
and face somatotopies. However, commingling of WM fibers from
the primary motor cortex regions localizing the face, upper limb
and lower limb somatotopies along the length of CST between the
CS and CP might reduce the sensitivity of detecting metabolite
alterations due to a specific dysfunctional body part. It is
speculated that the observed correlation between Cho/NAA in
the left CST and FVC (see Results section) may be due to this
inclusion of WM fibers from the face somatotopic region in the left
CST. However, further data analysis from the bilateral motor
cortical regions representing the somatotopies of the face and
respiratory muscles are needed to better understand such
correlations. Further studies are also needed to establish the
usefulness of CST segmental analysis in understanding the
temporal and spatial (anatomical) patterns of disease progression
in ALS. Certainly, our interpretation of the correlations between
Cho/NAA and FVC and finger tap rates has to be read with
caution as the volume of the processed MRS voxel was about
1c m
3 and that was interpolated to 8 mm
3 volume (2 mm
isotropic) for template space analysis.
As mentioned earlier, there is no previous whole intracranial
CST MRS study in the literature. However, considering the fact
that the CST atlas included data from the primary motor cortex,
our results are in agreement with previous findings of significant
associations between NAA [12,16] or NAA/Cre [18,36,38,39] or
NAA/Cho [10,19] or NAA/(Cho+Cre) [11] in the primary motor
cortex of patients with ALS and finger tap rate [11,16] or tests of
disease severity [10,12,16,18,19,36,38,39]. There are, however, a
few studies which have reported no correlations between the MRS
metrics (measured in this study) in the primary motor cortex and
measures of disease severity (ALSFRS-R; [9,12,40]) or finger or
foot tapping rate [9,40]. The lack of consistently observed
correlations between the MRS metrics and disease severity or
UMN function measures in previous MRS studies may be due to
inclusion of a heterogeneous patient population with a wide range
Table 3. P-values of the metabolite comparisons between the intracranial CST segments in each hemisphere in the control group.
Metabolite Region Control Left Intracranial-CST Control Right Intracranial-CST
CP CR CS PCG CP CR CS PCG
NAA CP
CR 1 0.015*
CS 0.016* 0.001* 1 ,0.0001*
PCG ,0.0001* ,0.0001* ,0.0001* ,0.0001* ,0.0001* ,0.0001*
PLIC 0.003* 0.001* ,0.0001* ,0.0001* 0.010* 1 ,0.0001* ,0.0001*
Cho CP
CR ,0.0001* ,0.0001*
CS ,0.0001* 0.031* ,0.0001* ,0.0001*
PCG ,0.0001* ,0.0001* ,0.0001* ,0.0001* ,0.0001* ,0.0001*
PLIC ,0.0001* 1 ,0.0005* ,0.0001* ,0.0001* 1 ,0.0001* ,0.0001*
Cre CP
CR 11
CS 0.007* 0.001* 1 0.007*
PCG ,0.0001* ,0.0001* 0.001* 0.001* ,0.0001* 0.030*
PLIC 0.001* ,0.0005* ,0.0001* ,0.0001* 0.075 1 ,0.0001* ,0.0001*
Cho/NAA CP
CR ,0.0001* ,0.0001*
CS ,0.0001* 1 ,0.0001* 1
PCG ,0.0001* ,0.0001* 0.001* ,0.0001* ,0.0001* ,0.0001*
PLIC ,0.0001* 0.986 1 0.007* ,0.0001* 1 1 ,0.0001*
Significant p-values (,0.05) are indicated by asterisks (*). Out of a total of 40 possible comparisons, 34 and 30 between-segment comparisons were found to be
significant in the left and right CST, respectively. The abbreviations used are: CST: corticospinal tract, PCG: precentral gyrus, CS: centrum semiovale, CR: corona radiate,
PLIC: posterior limb of internal capsule, and CP: cerebral peduncle, NAA: N-acetyl aspartate, Cho: total-choline, Cre: total-creatine.
doi:10.1371/journal.pone.0035607.t003
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metabolites with respect to disease duration and severity, and
global measures of disease severity (e.g., ALSFRS-R) not reflecting
localized MRS changes.
The MRS results of the CST segments show consistent trends
(decreased NAA, and increased Cho, Cre and Cho/NAA in ALS)
for the metabolite metrics along the length of the CST bilaterally
(Figure 5). The observation of significant changes in Cho/NAA of
patients with ALS in all of the CST segments bilaterally indicates
that the entire length of the CST between the PMC and CP was
affected. In contrast, significant bilaterally asymmetric changes in
NAA (only 4 segments in the left CST and no segments in the right
CST; Figure 5) and Cho (2 segments in the left and 3 segments in
the right; Figure 5) indicate spatial lateralization in the individual
metabolite alterations. Furthermore, the above findings suggest
presence of two spatially variant metabolic processes in our patient
population. The processes include decreased NAA in some
segments in the left intracranial CST and increased Cho in the
same or other segments, both of which might indicate varying
stages of degeneration of neurons and/or axons in the PMC and
CST. Although, as stated earlier, there are no methodologically
similar previous studies in the literature, our results are
qualitatively in agreement with findings from a previous study
[19] in that NAA/Cho (Cho/NAA in this study) was consistently
lower (higher in this study) across the length of the CST from the
precentral gyrus to CP in patients with ALS.
Limitations of this study include that the metabolite and water
relaxation times (T1 and T2) were not measured in the MRSI
acquisition method used, and therefore, not accounted for in our
metabolite signal normalization and quantitation methods. The
lengthy relaxation time measurements pose a practical difficulty of
including them in our whole-brain MRSI study protocol.
Therefore, the reported MRS metrics include possible contribu-
tions from altered metabolite relaxation times between the subjects
in the patient and control groups. Also, some of the patients
participated in this study were treated with riluzole either before
participating in this study or at the time of scan. Even though there
is no conclusive evidence [41,42] of altered metabolite concentra-
tions after taking riluzole, the confounding effects of this drug on
the metabolite metrics cannot be ruled out completely.
In conclusion, the results of this study demonstrate that
significant alterations of proton MRS-observed metabolites occur
in the entire intracranial CST, including the primary motor cortex
in patients with ALS. The significant correlations between the
clinical measures of a body part assessing UMN dysfunction and
the MRS metrics evaluated in the relevant body region of the
primary motor cortex in the ALS group suggest that the MRS
metrics can be potential biomarkers for mapping clinical signs of
UMN dysfunction in the relevant body region of the primary
motor cortex. The MRS acquisition and processing methods used
in this study are currently semi-automated but can be fully
automated for use in clinical settings. Finally, this study has shown
that the altered
1H-MRS metrics in the corticospinal tracts of
patients with ALS can be thoroughly characterized by acquiring
data from the whole intracranial CST and using an unbiased
evaluation method.
Table 4. P-values of the metabolite comparisons between the intracranial CST segments in each hemisphere in the ALS group.
Metabolite Region ALS Left Intracranial-CST ALS Right Intracranial-CST
CP CR CS PCG CP CR CS PCG
NAA CP
CR 11
CS ,0.0001* 0.027* 1 0.170
PCG ,0.0001* ,0.0001* ,0.0001* ,0.0001* ,0.0001* ,0.0001*
PLIC 1 0.089 ,0.0001* ,0.0001* 0.400 1 0.026* ,0.0001*
Cho CP
CR 0.003* 0.030*
CS ,0.0001* 0.557 ,0.0001* 0.209
PCG ,0.0001* ,0.0001* ,0.0001* ,0.0001* ,0.0001* ,0.0001*
PLIC 0.014* 1 1 ,0.0001* 0.063 1 0.168 ,0.0001*
Cre CP
CR 11
CS 0.015* 0.907 1 0.838
PCG ,0.0001* 0.003* 0.234 1 0.200 1
PLIC 1 0.155 ,0.0001* ,0.0001* 0.080 0.272 ,0.0001* ,0.0001*
Cho/NAA CP
CR 0.928 0.001*
CS 11 ,0.0005* 1
PCG ,0.0005* 0.043* 0.004* ,0.0001* 0.492 1
PLIC 0.002* 0.226 0.022* 1 ,0.0005* 1 1 0.970
Significant p-values (,0.05) are indicated by asterisks (*). Out of a total of 40 possible comparisons, 24 and 17 between-segment comparisons were found to be
significant in the left and right CST, respectively. The abbreviations used are: CST: corticospinal tract, PCG: precentral gyrus, CS: centrum semiovale, CR: corona radiate,
PLIC: posterior limb of internal capsule, and CP: cerebral peduncle, NAA: N-acetyl aspartate, Cho: total-choline, Cre: total-creatine.
doi:10.1371/journal.pone.0035607.t004
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